International Isotopes Expands Operational Footprint: A Strategic Move for Growth

International Isotopes, Inc. (OTCQB: INIS) has announced a strategic expansion of its operational footprint with the recent purchase of vacant land adjacent to its current Idaho Falls facility ("Building A") and the lease agreement, with the right to purchase, for a second building ("Building B") located directly across the street from their Idaho Falls facility. These forward-looking additions address both immediate needs for current operations and developing a comprehensive growth plan for the company.

The lease agreement for Building B will provide the Company with near-term capability to double operational capacity, which is expected to positively impact all existing business segments. The Company has also secured a First Right of Refusal to purchase Building B, which boasts an 8,600 sf facility on a 1.73 acre lot. The Company intends to be able to shed a short-term lease in the area to offset costs because of the lease of Building B. INIS formerly occupied Building B in 2014 for DUF4 processing.

The acquired Building A lot provides over 1.77 acres, with no zoning restrictions in regard to building coverage and height, allowing the lot to accommodate a facility that exceeds 50,000 sf. The purchase was conducted on a mix of cash and seller's financing. The acquisition aligns with the company's long-term vision of expanding its capabilities, maximizing synergies and efficiencies, and positioning itself for success in a constantly evolving radiopharmaceuticals market.

Shahe Bagerdjian, President & CEO of INIS, commented, "We need to always think a few steps forward and ensure we can seize on the opportunities that present themselves. These two additions will help us continue to strengthen our Theranostics, Nuclear Medicine, Cobalt, and Medical Devices segments. 2024 was an exciting time for our brands; RadQual, RadVent, EasyFill, and Radnostix, and I anticipate 2025 will be more transformative."



The strategic moves by INIS align with its long-term vision and growth plans in several ways. Expanding capabilities and maximizing synergies, positioning for success in a constantly evolving market, strengthening existing business segments, and seizing opportunities are all key aspects of the company's growth strategy. By expanding its operational footprint, INIS is well-positioned to capitalize on market trends and maintain a competitive edge in the radiopharmaceuticals industry.



In conclusion, International Isotopes, Inc.'s strategic expansion of its operational footprint through the acquisition of Building A and the lease of Building B is a forward-thinking move that aligns with the company's long-term vision and growth plans. By doubling operational capacity and expanding its capabilities, INIS is poised to strengthen its business segments and maintain a competitive edge in the constantly evolving radiopharmaceuticals market.